Citizens Jmp Raises BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $28.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price upped by Citizens Jmp from $25.00 to $28.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp’s price objective suggests a potential upside of 224.83% from the company’s previous close.

A number of other brokerages have also commented on BCRX. Royal Bank Of Canada lowered their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Weiss Ratings raised BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Needham & Company LLC lowered their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday. Wedbush lowered their price target on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Evercore began coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $20.70.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $8.62 on Thursday. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.31. The business’s fifty day moving average price is $9.08 and its two-hundred day moving average price is $7.83. The firm has a market capitalization of $2.19 billion, a PE ratio of -4.84 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The company had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. During the same period in the prior year, the business earned $0.20 earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 7.5% on a year-over-year basis. Equities research analysts expect that BioCryst Pharmaceuticals will post 0.26 earnings per share for the current fiscal year.

Insider Activity at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 150,000 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the transaction, the insider directly owned 400,703 shares of the company’s stock, valued at approximately $3,666,432.45. This trade represents a 27.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Larson Financial Group LLC boosted its stake in BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 3,267 shares in the last quarter. Focus Partners Wealth bought a new position in BioCryst Pharmaceuticals during the third quarter valued at about $77,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 2,115 shares in the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in BioCryst Pharmaceuticals during the fourth quarter valued at about $81,000. Finally, Farther Finance Advisors LLC boosted its stake in BioCryst Pharmaceuticals by 326.8% during the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 8,109 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.